Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sun Pharma is set to stop selling Oxaliplatin (generic Eloxatin) injection after June 30, 2010, following the US District Court's denial of the company's motion to suspend the court's order dated April 22, 2010 which entered a consent judgement and order having the effect of enjoining Sun Pharma from selling the product.
Subscribe to our email newsletter
Eloxatin is a registered trademark of sanofi aventis US. It is an antineoplastic that works by killing cancer cells and slowing tumor growth, is a cancer medication that interferes with the growth of cancer cells and slows their growth and spread in the body.
Following the court order dated April 22, 2010, Sun Pharma has appealed the court order and plans to litigate the matter before the US Court of Appeals for the Federal Circuit.
Sun Pharma believes that the bases for appeal are strong and plans to contest the entry of the Consent Judgement and Order. On receipt of a favorable judgement from the appellate court, Sun Pharma plans to reinitiate the sales of the product.